KB103, Krystal Biotech's lead gene therapy for recessive dystrophic epidermolysis bullosa, exhibited efficacy in healing wounds caused by the disorder after it reported full closure of five lesions by the 90th day after treatment based on data from its Phase I/II GEM trial. Krystal also disclosed that KB103 has been granted a regenerative medicine advanced therapy designation by the FDA.
Krystal Biotech touts efficacy of wound closure gene therapy candidate
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.